Coherus生物科学 CHRS 深 沪
已收盘 10-03 16:00:00 美东时间
1.64
-0.020
-1.20%
华盛通- 最 高1.70
- 今 开1.67
- 成交量 71.56万股
- 最 低 1.61
- 昨 收 1.66
- 总市值 1.90亿
- 52周最高 2.43
- 市盈率 静 6.61
- 换手率 0.00%
- 52周最低 0.6603
- 委 比 29.97%
- 总股本 1.16亿
- 历史最高 38.10
- 量 比 0.54
- 振 幅 5.42%
- 历史最低 0.6603
- 每 手 1
- 风险率 0.27%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Coherus Oncology Announces Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Coherus Oncology will present CHS-114, an anti-CCR8 monoclonal antibody, at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on November 8, 2025, in Maryland. Abstract #640 highlights its selective depletion of intratumoral Tregs and immune remodeling in advanced solid tumors. Additionally, CHS-114 will be featured in a SITC webinar on October 22, 2025, discussing CCR8's role in Treg activity and immunosuppression, with i...
10-03 13:05
辉瑞中国“潮起钱塘·智启未来”第二届智慧医疗创新生态大会在杭州举办
经济观察网9月19日至20日，辉瑞中国“潮起钱塘·智启未来”第二届智慧医疗创新生态大会在杭州举办。此次大会，辉瑞现场带来V-Track院内药品科学管...
09-24 17:43
Coherus Biosciences Regains Nasdaq Compliance
An update from Coherus Biosciences ( ($CHRS) ) is now available. On June 30, 20...
09-08 22:18
报名开启！辉瑞中国•第二届智慧医疗创新生态大会即将在杭启幕
（来源：动脉网） 当前，全球医药产业的核心竞争力已由单一的药物研发创新迈向“超越药片”的创新解决方案的新阶段，MNC正在重新定义自身的战略边界与发展路径。 医...
09-08 11:25
This Brinker International Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
Top Wall Street analysts changed their outlook on these top names. For a comple...
09-04 22:05
Maxim Group Upgrades Coherus Oncology to Buy, Announces $4 Price Target
Maxim Group analyst Jason McCarthy upgrades Coherus Oncology (NASDAQ:CHRS) from Hold to Buy and announces $4 price target.
09-04 20:09
Coherus Oncology to Participate in Upcoming Investor Conferences
Coherus Oncology announced its participation in three upcoming conferences: the Baird Global Healthcare Conference on September 9, 2025; the H.C. Wainwright Global Investment Conference on September 10, 2025; and UBS Virtual Oncology Day on October 1, 2025. Presentations will be available via webcast on the company's Investor Events page, with replays accessible for 30 days. Coherus, focused on advancing its oncology portfolio, including its PD-1...
09-03 12:30
Coherus BioSciences Q2 Adj. EPS $(0.34) Misses $(0.28) Estimate, Sales $10.254M Miss $10.946M Estimate
Coherus BioSciences (NASDAQ:CHRS) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.28) by 22.74 percent. This is a 142.86 percent decrease over losses of $(0.14) per share
08-08 05:16
Here are the major earnings after the close Thursday
Major earnings expected after the bell on Thursday include: Block (XYZ) Gilead Sciences (GILD) Twilio (TWLO) The Trade Desk (TTD) Main Street Capital Corporation (MAIN) Other earnings slated for rele...
08-07 22:00
Earnings Scheduled For August 7, 2025
Companies Reporting Before The Bell • GoHealth (NASDAQ:GOCO) is estimated to re...
08-07 16:33
